How Will the Metastatic HR+/HER2- Breast Cancer Market Grow? Key Trends and Opportunities for 2025 and Beyond
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How Will the Metastatic HR+/HER2- Breast Cancer Market Grow Over the Forecast Period Based on Its Expected CAGR?
The market size for metastatic HR+/HER2-breast cancer has experienced rapid expansion in the past few years. The size is projected to increase from $9.91 billion in 2024 to $10.92 billion in 2025, with a compound annual growth rate (CAGR) of 10.3%. This growth during the historic period can be credited to heightened awareness about early detection, improved diagnosis rates, successful clinical trials, investments in the pharmaceutical sector, and the rising popularity of combination therapies.
The market for metastatic HR+/HER2- breast cancer is predicted to witness robust expansion in the upcoming years. By 2029, it is anticipated to escalate to a value of $15.94 billion, with a compound annual growth rate (CAGR) of 9.9%. Several factors can be credited for the expected growth during the forecast era such as rising acceptance of pioneering therapies, heightened immunotherapy usage, penetration to emerging markets, programs for patient advocacy and support, along with concentration on enhancements in quality of life. Foreseen trends during the projection period encompass next-generation sequencing (NGS), progress in liquid biopsy, discovery of biomarkers, cell and gene therapy, along with monoclonal antibodies (mAbs).
How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the Metastatic HR+/HER2- Breast Cancer Market?
The growth of the metastatic HR+/HER2- breast cancer market is predicted to be driven by the escalating use of hormone replacement therapy (HRT). This medical procedure is utilized to augment or substitute hormones existing in insufficient quantities within the body, typically in situations like menopause or hormone deficiencies. The rise in HRT usage is attributed to its demonstrated efficacy in boosting treatment results, fewer adverse reactions compared to conventional methods, and the progress in precision medicine. Hormone replacement therapy can address the symptoms linked to estrogen deficiency due to menopause without hampering the success of endocrine treatments. This is because it primarily addresses hormonal discrepancies and not the cancerous cells. For instance, data from NHS England reveals that in 2022-23, 11 million HRT items were prescribed, indicating a 47% surge from 2021-22. Consequently, the increasing use of hormone replacement therapy stimulates the expansion of the metastatic HR+/HER2- breast cancer market, improving patient quality of life during cancer treatment.
Get Your Free Sample of the Global Metastatic HR+/HER2- Breast Cancer Market Report Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21220&type=smp
Who Are the Dominant Players Expanding Their Reach in the Metastatic HR+/HER2- Breast Cancer Market?
Major companies operating in the metastatic HR+/HER2- breast cancer market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hengrui Medicine Co Ltd., MacroGenics Inc., Arvinas Inc., Olema Pharmaceuticals Inc., CytomX Therapeutics Inc., G1 Therapeutics Inc., Context Therapeutics Inc., Celcuity Inc., Sermonix Pharmaceuticals Inc., Ambrx Biopharma Inc., Carrick Therapeutics
What Are the Top Trends Shaping the Evolution of the Metastatic HR+/HER2- Breast Cancer Market?
Leading enterprises in the metastatic HR+/HER2- breast cancer sector are looking to broaden their therapeutic scope, market influence, and treatment options by advancing combination therapy. This treatment strategy combines the use of multiple therapeutic agents, such as chemotherapy, targeted therapies, immunotherapy, hormone therapy, or other methods, with the goal of better targeting diverse pathways, increasing the overall efficiency of treatment, and minimizing the chances of conditions, like cancer, becoming resistant to a single treatment method. For example, in July 2023, the America-based pharmaceutical firm Merck & Co., Inc. announced the success of its Phase 3 KEYNOTE-756 trial which evaluated the effectiveness of KEYTRUDA (pembrolizumab), an anti-PD-1 treatment, in conjunction with chemotherapy that was approved by the US-based Food and Drug Administration. The trial was successful in its primary target of significantly improving the pathological complete response rate (pCR) in patients with high-risk, early-stage ER+/HER2- breast cancer. It marked the first positive Phase 3 trial to show a significant statistical improvement in the pCR with an immunotherapy regimen in a neoadjuvant setting for a particular patient demographic. The trial evaluated the use of KEYTRUDA with chemotherapy as an initial treatment, which was then followed by additional KEYTRUDA plus endocrine therapy for high-risk, early-stage ER+/HER2- breast cancer.
Get Instant Access to the Global Metastatic HR+/HER2- Breast Cancer Market Report with Swift Delivery!
Which Market Segments Are Driving Strategic Growth and Trends in the Metastatic HR+/HER2- Breast Cancer Market?
The metastatic HR+/HER2- breast cancer market covered in this report is segmented –
1) By Drugs: Paclitaxel, Tamoxifen, Vinblastine, Raloxifene, Docetaxel, Other Drugs
2) By Treatment: Radiation Therapy, Vitamin Therapy, Macrobiotic Diets, Homeopathy, Herbal Medication
3) By End-User: Hospitals, Clinics, Other End-User
Subsegments:
1) By Paclitaxel: Generic Paclitaxel, Taxol
2) By Tamoxifen: Generic Tamoxifen, Nolvadex
3) By Vinblastine: Generic Vinblastine, Velban
4) By Raloxifene: Generic Raloxifene, Evista
5) By Docetaxel: Generic Docetaxel, Taxotere
6) By Other Drugs: Letrozole, Anastrozole, Exemestane, Palbociclib, Ribociclib, Abemaciclib
Which Regions Are Setting the Pace for Metastatic HR+/HER2- Breast Cancer Market Growth?
North America was the largest region in the dominated market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metastatic HR+/HER2- breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Is the Metastatic HR+/HER2- Breast Cancer Market Defined Across Different Regions?
Metastatic HR+/HER2- breast cancer refers to a form of breast cancer where the cancer cells have spread beyond the breast to other parts of the body. Metastatic HR+/HER2- breast cancer is treated using targeted therapies, hormonal treatments, and chemotherapy to manage disease progression and improve patient outcomes.
Browse Through More Similar Reports By The Business Research Company:
Kidney Transplant Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/kidney-transplant-global-market-report
Chronic Kidney Disease Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/chronic-kidney-disease-global-market-report
Pediatric Vaccine Global Market Report 2025
https://thebusinessresearchcompany.com/report/pediatric-vaccine-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
